flutamide has been researched along with Bone Cancer in 61 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo." | 5.08 | Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. ( Blumenstein, BA; Bueschen, AJ; Crawford, ED; Culkin, DJ; Eisenberger, MA; Loehrer, PJ; Lowe, BA; McLeod, DG; Miller, G; Sears, K; Thompson, IM; Wilding, G, 1998) |
| "5) conducted by the Scandinavian Prostate Cancer Group comparing parenteral estrogen with total androgen blockade." | 2.82 | Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. ( Berglund, A; Hedlund, PO; Klaff, R; Sandblom, G; Varenhorst, E, 2016) |
| "For good prognosis metastatic prostate cancer patients under anti-androgen treatment, PSA response at 6 months with cut-off levels of < or = 1 ng/ml and < or = 10 ng/ml is prognostic for survival." | 2.71 | Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). ( Collette, L; de Reijke, TM; Schröder, FH, 2003) |
| "The primary clinical events were disease progression and survival." | 2.69 | Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. ( Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ, 1999) |
| ") monotherapy at a daily dose of 100 mg, which is the most commonly used dosage in Japan for patients with prostatic cancer." | 2.67 | A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group. ( Akaza, H; Aso, Y; Koiso, K; Kotake, T; Usami, M, 1993) |
| "A total of 327 patients with metastatic prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex depot supplemented by flutamide 250 mg 3 qid." | 2.67 | Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group. ( Bond, A; Carvalho, AP; De Pauw, M; Denis, L; Keuppens, F; Newling, D; Ongena, P; Smith, P; Sylvester, R; Vermeylen, K, 1990) |
| "Only one patient has died from prostate cancer while 3 have died from other causes." | 2.66 | Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. ( Belanger, A; Bergeron, V; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacoursiere, Y; Monfette, G, 1985) |
| "All estramustine-treated patients lost their libido, whereas only 20 per cent of the patients treated with flutamide did so." | 2.66 | Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. ( Andersson, SO; Beckman, KW; Johansson, JE; Lingårdh, G; Zador, G, 1987) |
| "Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy." | 2.65 | Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. ( Sogani, PC; Vagaiwala, MR; Whitmore, WF, 1984) |
| "Flutamide monotherapy is an alternative for some patients." | 2.49 | First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease. ( , 2013) |
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| "Ninety-five patients with prostate cancer were divided into one of three groups: 26 patients with bone metastasis (BM(+)), 35 patients without bone metastasis on nonhormonal therapy (BM(-)HT(-)) and 34 patients without bone metastasis on hormonal therapy (BM(-)HT(+))." | 1.31 | Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. ( Fukunaga, M; Jo, Y; Sone, T; Tamada, T; Tanaka, H; Tomomitsu, T, 2001) |
| "African-American men with metastatic prostate cancer have a statistically significantly worse prognosis than white men that cannot be explained by the prognostic variables explored in this study." | 1.31 | Association of African-American ethnic background with survival in men with metastatic prostate cancer. ( Crawford, E; Eisenberger, M; Moinpour, C; Tangen, C; Thompson, I; Tolcher, A, 2001) |
| "Four of the patients died of prostate cancer." | 1.31 | M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. ( Aizawa, T; Akiyama, A; Ito, T; Miki, M; Tachibana, M; Yamamoto, S, 2001) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen-independence is frequently observed later." | 1.31 | Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. ( Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T, 2002) |
| "Patients with progressive prostate cancer were treated with bicalutamide 200 mg daily." | 1.30 | Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. ( Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L, 1997) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen independence is frequently observed." | 1.30 | Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. ( Akakura, K; Akimoto, S; Furuya, Y; Igarashi, T; Ito, H; Murakami, S; Shimazaki, J, 1998) |
| "Secondary testicular tumors are very rare." | 1.29 | [Bilateral testicular metastasis of an adenocarcinoma of the prostate]. ( Agnanti, N; Bai, M; Giannakopoulos, X; Grammeniatis, E; Stefanou, D, 1994) |
| "Fourty-eight patients with stage D2 prostate cancer, initially treated with endocrine therapy at the University of Tokyo between 1981 and 1990, were followed up and analysed." | 1.29 | [Objective and subjective response in stage D2 prostate cancer patients with cancer pain]. ( Aso, Y; Higashihara, E; Hirasawa, K; Homma, Y; Kasuya, Y; Kawabe, K; Tanaka, Y; Yoshida, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (18.03) | 18.7374 |
| 1990's | 33 (54.10) | 18.2507 |
| 2000's | 13 (21.31) | 29.6817 |
| 2010's | 4 (6.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Höfner, T | 1 |
| Vallet, S | 1 |
| Hadaschik, BA | 1 |
| Pahernik, S | 1 |
| Duensing, S | 1 |
| Hohenfellner, M | 1 |
| Jäger, D | 1 |
| Grüllich, C | 1 |
| Varenhorst, E | 2 |
| Klaff, R | 1 |
| Berglund, A | 1 |
| Hedlund, PO | 2 |
| Sandblom, G | 1 |
| Oh, WK | 1 |
| Manola, J | 1 |
| Bittmann, L | 1 |
| Brufsky, A | 1 |
| Kaplan, ID | 1 |
| Smith, MR | 1 |
| Kaufman, DS | 1 |
| Kantoff, PW | 1 |
| Collette, L | 1 |
| de Reijke, TM | 1 |
| Schröder, FH | 1 |
| Yamamoto, S | 2 |
| Yonese, J | 1 |
| Kawakami, S | 1 |
| Tsukamoto, T | 1 |
| Ohkubo, Y | 1 |
| Tatokoro, M | 1 |
| Fukui, I | 1 |
| Metzner, C | 1 |
| Nöldge, G | 1 |
| Delling, G | 1 |
| Oehler, U | 1 |
| Nawroth, P | 1 |
| Kasperk, C | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Lin, CJ | 1 |
| Hsieh, RK | 1 |
| Lim, KH | 1 |
| Chen, HH | 1 |
| Cheng, YC | 1 |
| Wu, CJ | 1 |
| Sartor, AO | 1 |
| Tangen, CM | 1 |
| Hussain, MH | 1 |
| Eisenberger, MA | 2 |
| Parab, M | 1 |
| Fontana, JA | 1 |
| Chapman, RA | 1 |
| Mills, GM | 1 |
| Raghavan, D | 1 |
| Crawford, ED | 3 |
| Damber, JE | 1 |
| Hagerman, I | 1 |
| Haukaas, S | 1 |
| Henriksson, P | 1 |
| Iversen, P | 1 |
| Johansson, R | 1 |
| Klarskov, P | 1 |
| Lundbeck, F | 1 |
| Rasmussen, F | 1 |
| Viitanen, J | 1 |
| Sogani, PC | 1 |
| Vagaiwala, MR | 1 |
| Whitmore, WF | 1 |
| Soloway, MS | 2 |
| Narayana, AS | 1 |
| Loening, SA | 1 |
| Culp, DA | 1 |
| Cooper, EH | 2 |
| Whelan, P | 3 |
| Purves, D | 1 |
| Brenner, PC | 1 |
| Rettig, WJ | 1 |
| Sanz-Moncasi, MP | 1 |
| Reuter, V | 1 |
| Aprikian, A | 1 |
| Old, LJ | 1 |
| Fair, WR | 1 |
| Garin-Chesa, P | 1 |
| Akaza, H | 1 |
| Usami, M | 1 |
| Kotake, T | 1 |
| Koiso, K | 1 |
| Aso, Y | 2 |
| Giannakopoulos, X | 1 |
| Bai, M | 1 |
| Grammeniatis, E | 1 |
| Stefanou, D | 1 |
| Agnanti, N | 1 |
| Labrie, F | 7 |
| Dupont, A | 7 |
| Cusan, L | 5 |
| Gomez, JL | 1 |
| Diamond, P | 1 |
| Yoshida, M | 1 |
| Hirasawa, K | 1 |
| Kasuya, Y | 1 |
| Tanaka, Y | 1 |
| Homma, Y | 1 |
| Higashihara, E | 1 |
| Kawabe, K | 1 |
| Newling, DW | 3 |
| Denis, L | 6 |
| Vermeylen, K | 2 |
| Denis, LJ | 2 |
| Carnelro de Moura, JL | 1 |
| Bono, A | 4 |
| Sylvester, R | 6 |
| Newling, D | 3 |
| Depauw, M | 1 |
| Fernández Peña, CM | 1 |
| Morano Amado, LE | 1 |
| Montes Santiago, J | 1 |
| Fachal, C | 1 |
| Pantel, K | 1 |
| Enzmann, T | 1 |
| Köllermann, J | 1 |
| Caprano, J | 1 |
| Riethmüller, G | 1 |
| Köllermann, MW | 1 |
| Scher, HI | 1 |
| Liebertz, C | 1 |
| Kelly, WK | 1 |
| Mazumdar, M | 1 |
| Brett, C | 1 |
| Schwartz, L | 1 |
| Kolvenbag, G | 1 |
| Shapiro, L | 1 |
| Schwartz, M | 1 |
| Satoh, T | 1 |
| Egawa, S | 1 |
| Katsuta, M | 1 |
| Iwamura, M | 1 |
| Uchida, T | 1 |
| Koshiba, K | 1 |
| Losa, M | 1 |
| Grasso, M | 1 |
| Giugni, E | 1 |
| Mortini, P | 1 |
| Acerno, S | 1 |
| Giovanelli, M | 1 |
| Sylvester, RJ | 1 |
| de Voogt, H | 1 |
| Keuppens, F | 3 |
| Smith, PH | 4 |
| de Moura, JL | 2 |
| Furuya, Y | 2 |
| Akimoto, S | 2 |
| Akakura, K | 1 |
| Igarashi, T | 1 |
| Murakami, S | 1 |
| Shimazaki, J | 2 |
| Ito, H | 1 |
| Longmore, L | 1 |
| Foley, JP | 1 |
| Rozanski, TA | 1 |
| Higgins, B | 1 |
| Thompson, IM | 2 |
| Blumenstein, BA | 1 |
| Miller, G | 1 |
| McLeod, DG | 2 |
| Loehrer, PJ | 1 |
| Wilding, G | 1 |
| Sears, K | 1 |
| Culkin, DJ | 1 |
| Bueschen, AJ | 1 |
| Lowe, BA | 1 |
| Schellhammer, PF | 1 |
| Vogelzang, NJ | 1 |
| Sharifi, R | 1 |
| Block, NL | 1 |
| Venner, PM | 1 |
| Patterson, AL | 1 |
| Sarosdy, MF | 1 |
| Kelley, RP | 1 |
| Kolvenbag, GJ | 1 |
| Tamada, T | 1 |
| Sone, T | 1 |
| Tomomitsu, T | 1 |
| Jo, Y | 1 |
| Tanaka, H | 1 |
| Fukunaga, M | 1 |
| Thompson, I | 1 |
| Tangen, C | 1 |
| Tolcher, A | 1 |
| Crawford, E | 1 |
| Eisenberger, M | 1 |
| Moinpour, C | 1 |
| Rapoport, J | 1 |
| Ito, T | 1 |
| Akiyama, A | 1 |
| Aizawa, T | 1 |
| Miki, M | 1 |
| Tachibana, M | 1 |
| Nozaki, T | 1 |
| Nagakawa, O | 1 |
| Fuse, H | 1 |
| Higa, T | 1 |
| Masai, M | 1 |
| Isaka, S | 1 |
| Zaragoza, MR | 1 |
| Grossman, HB | 1 |
| Long, JP | 1 |
| Prout, GR | 1 |
| Huben, RP | 1 |
| Armitage, TG | 2 |
| Robinson, MR | 1 |
| Richards, BR | 1 |
| Berná, L | 1 |
| Germá, JR | 1 |
| Estorch, M | 1 |
| Torres, G | 1 |
| Blanco, R | 1 |
| Carrió, I | 1 |
| Corkery, JC | 1 |
| Bihrle, W | 1 |
| McCaffrey, JA | 1 |
| Whitcomb, FF | 1 |
| Levy, C | 1 |
| Ellis, R | 1 |
| Allen, JA | 1 |
| Calais da Silva, F | 1 |
| Debruyne, F | 1 |
| Robinson, P | 1 |
| Smith, P | 1 |
| Carvalho, AP | 1 |
| Bond, A | 1 |
| De Pauw, M | 2 |
| Ongena, P | 1 |
| Robinson, M | 1 |
| Mahler, C | 1 |
| Boccardo, F | 1 |
| Decensi, A | 1 |
| Guarneri, D | 1 |
| Rubagotti, A | 1 |
| Oneto, F | 1 |
| Martorana, G | 1 |
| Giuliani, L | 1 |
| Delli Ponti, U | 1 |
| Petracco, S | 1 |
| Cortellini, P | 1 |
| Bélanger, A | 5 |
| Lacourcière, Y | 2 |
| Béland, L | 1 |
| Lachance, R | 2 |
| Gomez, J | 1 |
| Emond, J | 3 |
| Monfette, G | 3 |
| Manhès, G | 1 |
| Bergeron, N | 1 |
| Pineault, S | 1 |
| Giguere, M | 2 |
| Lacoursiere, Y | 1 |
| Bergeron, V | 1 |
| Brochu, M | 1 |
| O'Brien, WM | 1 |
| Lynch, JH | 1 |
| Johansson, JE | 2 |
| Andersson, SO | 2 |
| Beckman, KW | 2 |
| Zador, G | 2 |
| Lingårdh, G | 1 |
| Lundgren, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer[NCT01875250] | Phase 2 | 38 participants (Actual) | Interventional | 2013-07-22 | Completed | ||
| Collection of Blood From Patients With Prostate Cancer[NCT00923221] | 1,000 participants (Anticipated) | Observational | 2007-02-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Normal testosterone is 270-1070 nd/dL. (NCT01875250)
Timeframe: 84 days
| Intervention | ng/dl (Median) |
|---|---|
| All Participants | 834 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01875250)
Timeframe: Date treatment consent signed to date off study, approximately 43 months and 13 days for Arm A, and 78 months and 6 days for Arm B.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 19 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 19 |
Median PSA change would be considered optimal. (NCT01875250)
Timeframe: 84 days
| Intervention | Percent change (Median) |
|---|---|
| Arm A - Enzalutamide for 3 Months | -99 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | -99 |
Growth rate was measured using the growth rate equation -f(t) = exp (-d*t) + exp (g*t) -1 where exp is the base of the natural algorithm, e = 2.7182 and t is days since treatment started. The tumor growth rate equation measures Prostate Specific Antigen (PSA) rise over time. The UOM is unitless because this is a way to measure PSA kinetics. (NCT01875250)
Timeframe: 7 months
| Intervention | unitless (Number) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 0.031 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 0.030 |
VEGF was measured by the enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantitation of assay was 9.0 pg/ml. (NCT01875250)
Timeframe: 30 Days After the Start of Course 1 and Course 2 of Enzalutamide
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 192 | 165.04 |
PSA recovery is defined as the return above baseline PSA in participants with normal testosterone and non-metastatic, castration sensitive prostate cancer. (NCT01875250)
Timeframe: up to 41 months
| Intervention | Days (Median) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 224 | 189 |
3 reviews available for flutamide and Bone Cancer
| Article | Year |
|---|---|
First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cyproterone; Estrogens; Fluta | 2013 |
[Fulminant liver failure with a fatal outcome due to flutamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Fatal Outcome; Flutamide; Hep | 1997 |
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
Topics: Anilides; Bone Neoplasms; Combined Modality Therapy; Flutamide; Humans; Male; Multicenter Studies as | 1989 |
25 trials available for flutamide and Bone Cancer
| Article | Year |
|---|---|
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Flutamide; Humans; Male; M | 2016 |
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antin | 2003 |
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyprote | 2003 |
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Fre | 2008 |
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Cause of Death; Estradiol; Estrogens; | 2008 |
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Anilides; Bone Neoplasms; Clinical Trials as Topic; F | 1984 |
A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Confidence Intervals; Double-Blind M | 1993 |
Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modal | 1993 |
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Flutamide; Goserelin; Humans; Liver | 1993 |
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Stu | 1993 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 1998 |
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 1998 |
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modal | 1998 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agent | 1999 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Evaluati | 1990 |
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Stud | 1990 |
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Gosereli | 1990 |
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busereli | 1990 |
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-U | 1990 |
Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Canada; Flutamide; H | 1990 |
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
Topics: Anilides; Bone Neoplasms; Combined Modality Therapy; Flutamide; Humans; Male; Multicenter Studies as | 1989 |
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.
Topics: Acid Phosphatase; Anilides; Bone and Bones; Bone Neoplasms; Dehydroepiandrosterone; Dehydroepiandros | 1985 |
Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Anilides; Bone Neoplasms; Estramustine; Flutamide; Follow-Up Studies; Humans; | 1988 |
Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Bone Neoplasms; Estramustine; Flutamide; Humans; | 1987 |
34 other studies available for flutamide and Bone Cancer
| Article | Year |
|---|---|
Choice of first-line treatment for metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Estrogens; Flutamide; Goserel | 2013 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic C | 2015 |
Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[Bone metastasis of prostatic cancer imitating Paget's sarcoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neopla | 2006 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2007 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonad | 1984 |
Flutamide in the treatment of metastatic carcinoma of the prostate.
Topics: Aged; Anilides; Bone Neoplasms; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms | 1981 |
Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Cy | 1994 |
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Neoplasms; Flutamide; Glycoproteins | 1995 |
[Bilateral testicular metastasis of an adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Combined Modality Therapy; Flutamide; Humans; Male; Orchiectom | 1994 |
[Objective and subjective response in stage D2 prostate cancer patients with cancer pain].
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diethylstilbestrol; Flutamide; Follow-Up Studies; Humans; M | 1994 |
Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemo | 1997 |
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; | 1997 |
[A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer].
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Chemical and Drug Induced Liver Injury; Flutamide; Human | 1997 |
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Diagno | 1997 |
Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgens; Blood Chemical Analysis; Bone Neoplasms; C | 1998 |
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brac | 1998 |
Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2001 |
Association of African-American ethnic background with survival in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Black or African Ame | 2001 |
Oncogenic osteomalacia.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Cholecalciferol; Disease Progression; Fatal Outcome; Flutamide | 2000 |
M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL.
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy, Needle; Bone Neoplasms; Carcinoembryonic Antigen; Cel | 2001 |
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Ac | 2002 |
Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Combined Modality Therapy; Estrogens | 1992 |
Objective treatment response to endocrine therapy in metastatic prostate cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Combined Modality Therapy; Estrogens; Flutamide; Humans; Lymphatic M | 1992 |
The usefulness of serum acid phosphatase in monitoring patients with advanced prostate carcinoma.
Topics: Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Cyclophosphamide; Estramustine; | 1992 |
Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasm | 1990 |
Bone marrow regeneration after hormonal therapy in patients with bone metastases from prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Bone Neoplasms; Buserelin; Flutamide; | 1991 |
Flutamide-related fulminant hepatic failure.
Topics: Bone Neoplasms; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Male; Middle Aged; Prosta | 1991 |
Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1990 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstene | 1988 |
Hydroxyproline as a marker for following patients with metastatic prostate cancer.
Topics: Bone Neoplasms; Buserelin; Creatinine; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; | 1988 |
Flutamide as primary treatment for metastatic prostatic cancer.
Topics: Aged; Aged, 80 and over; Anilides; Bone Neoplasms; Flutamide; Humans; Male; Middle Aged; Prostatic N | 1987 |
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Topics: Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; M | 1985 |